[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625940":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":20,"responsibleParty":21,"collaborators":20,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":30,"acronym":20,"eligibilityCriteria":31,"healthyVolunteers":27,"sex":32,"minAge":33,"maxAge":20,"enrollmentInfo":34,"targetDuration":20,"studyType":37,"phases":38,"briefSummary":40,"conditions":41,"keywords":20,"overallStatus":45,"whyStopped":20,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":20},{"fullName":5,"class":6},"Alberta Health services","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment","EXPERIMENTAL","Use of Mycobacteriophage",[13],"Biological: DP-QB-MYA-002",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","DP-QB-MYA-002","In-vitro effective Mycobacteriophage DP-QB-MYA-002 against specific strain of Mycobacterium abscessus ssp abscessuss",[9],null,{"type":22,"investigatorFullName":23,"investigatorTitle":24,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Jenny Edwards","Doctor of Pharmacy","100625940","phase-1-bacteriophage-for-chronic-multidrug-resistant-mycobacterium-abscessus-subsp-abscessus-pulmonary-infection-100625940",false,"NCT07429162","Bacteriophage for Chronic Multidrug-Resistant Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection","DP-QB-MYA-002 Phage Cocktail for Chronic Multidrug-Resistant (MDR) Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection","Inclusion Criteria:\n\n* Consent to participation\n\nExclusion Criteria:\n\n* non-consent to participation","ALL","18 Years",{"count":35,"type":36},1,"ESTIMATED","INTERVENTIONAL",[39],"PHASE1","The objective of this study is to evaluate mycobacteriophage therapy using in-vitro validated mycobacteriophage DP-QB-MYA-002 in combination with conventional antimycobacterial agents for the treatment of multidrug-resistant Mycobacterium abscessus pulmonary disease, with the goal of reducing mycobacterial burden and improving pulmonary outcomes.",[42,43,44],"Mycobacterium Abscessus Infection","Bacteriophage Therapy","Pulmonary Disease","NOT_YET_RECRUITING","2026-02-17",{"date":48,"type":49},"2026-02-24","ACTUAL",{"date":51,"type":36},"2026-07-02",{"date":53,"type":36},"2028-07-02",{"name":5,"class":6}]